Molecular Life Sciences

Living Edition
| Editors: Robert D. Wells, Judith S. Bond, Judith Klinman, Bettie Sue Siler Masters, Ellis Bell

Gyrase and Topoisomerase IV as Targets for Antibacterial Drugs

  • Adam C. Ketron
  • Katie J. Aldred
  • R. Hunter Lindsey
  • Neil Osheroff
Living reference work entry


Beyond their essential cellular functions, the bacterial type II topoisomerases, gyrase and topoisomerase IV, are targets for quinolone-based drugs. Quinolones are the most efficacious and broad-spectrum oral antibacterial agents currently in clinical use. Similar to the topoisomerase-targeted anticancer drugs, quinolones are topoisomerase II poisons that increase the levels of gyrase- and topoisomerase IV-DNA cleavage complexes. Both bacterial type II enzymes appear to be physiological targets of quinolones; however, the relative contributions of gyrase and topoisomerase IV to quinolone efficacy appear to be strain and drug specific. Initial resistance to quinolones usually results from specific point mutations in gyrase or topoisomerase IV. Recent models for quinolone-enzyme interactions may help to develop novel drugs that overcome resistance. Finally, a number of non-quinolone drugs display activity against gyrase and topoisomerase IV and are in development.




Quinolone Resistance Torsional Stress Cleavage Complex Oxolinic Acid Multidrug Efflux Pump 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.


  1. Aldred KJ, McPherson SA, Wang P, Kerns RJ, Graves DE, Turnbough CL Jr, Osheroff N (2012) Drug interactions with Bacillus anthracis topoisomerase IV: biochemical basis for quinolone action and resistance. Biochemistry 51:370–381PubMedCentralPubMedCrossRefGoogle Scholar
  2. Aldred KJ, McPherson SA, Turnbough CL Jr, Kerns RJ, Osheroff N (2013) Topoisomerase IV-quinolone interactions are mediated through a water-metal ion bridge: mechanistic basis of quinolone resistance. Nucleic Acids Res 41:4628–4639PubMedCentralPubMedCrossRefGoogle Scholar
  3. Aldred KJ, Kerns RJ, Osheroff N (2014) Mechanism of quinolone action and resistance. Biochemistry 53:1565–15674PubMedCrossRefGoogle Scholar
  4. Anderson VE, Osheroff N (2001) Type II topoisomerases as targets for quinolone antibacterials: turning Dr. Jekyll into Mr. Hyde. Curr Pharm Des 7:337–353PubMedCrossRefGoogle Scholar
  5. Anderson VE, Zaniewski RP, Kaczmarek FS, Gootz TD, Osheroff N (1999) Quinolones inhibit DNA religation mediated by Staphylococcus aureus topoisomerase IV. Changes in drug mechanism across evolutionary boundaries. J Biol Chem 274:35927–35932PubMedCrossRefGoogle Scholar
  6. Champoux JJ (2001) DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem 70:369–413PubMedCrossRefGoogle Scholar
  7. Collin F, Karkare S, Maxwell A (2011) Exploiting bacterial DNA gyrase as a drug target: current state and perspectives. Appl Microbiol Biotechnol 92:479–497PubMedCentralPubMedCrossRefGoogle Scholar
  8. Drlica K, Hiasa H, Kerns R, Malik M, Mustaev A, Zhao X (2009) Quinolones: action and resistance updated. Curr Top Med Chem 9:981–998PubMedCentralPubMedGoogle Scholar
  9. Gellert M, Mizuuchi K, O’Dea MH, Itoh T, Tomizawa JI (1977) Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity. Proc Natl Acad Sci U S A 74:4772–4776PubMedCentralPubMedCrossRefGoogle Scholar
  10. Khodursky AB, Zechiedrich EL, Cozzarelli NR (1995) Topoisomerase IV is a target of quinolones in Escherichia coli. Proc Natl Acad Sci U S A 92:11801–11805PubMedCentralPubMedCrossRefGoogle Scholar
  11. Morgan-Linnell SK, Becnel Boyd L, Steffen D, Zechiedrich L (2009) Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates. Antimicrob Agents Chemother 53:235–241PubMedCentralPubMedCrossRefGoogle Scholar
  12. Sugino A, Peebles CL, Kreuzer KN, Cozzarelli NR (1977) Mechanism of action of nalidixic acid: purification of Escherichia coli nalA gene product and its relationship to DNA gyrase and a novel nicking-closing enzyme. Proc Natl Acad Sci U S A 74:4767–4771PubMedCentralPubMedCrossRefGoogle Scholar
  13. Wohlkonig A, Chan PF, Fosberry AP, Homes P, Huang J, Kranz M, Leydon VR, Miles TJ, Pearson ND, Perera RL, Shillings AJ, Gwynn MN, Bax BD (2010) Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance. Nat Struct Mol Biol 17:1152–1153PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Adam C. Ketron
    • 1
  • Katie J. Aldred
    • 1
  • R. Hunter Lindsey
    • 1
  • Neil Osheroff
    • 1
  1. 1.Department of Biochemistry and the Vanderbilt Institute of Chemical BiologyVanderbilt University, School of MedicineNashvilleUSA